Da-Yo Yuh1, Ting-Han Chang2, Ren-Yeong Huang1, Wu-Chien Chien3, Fu-Gong Lin3, Earl Fu4. 1. Department of Periodontology, School of Dentistry, National Defense Medical Center and Tri-Service General Hospital, Taipei, Taiwan. 2. Department of Oral and Maxillofacial Surgery, School of Dentistry, National Defense Medical Center and Tri-Service General Hospital, Taipei, Taiwan. 3. School of Public Health, National Defense Medical Center, Taipei, Taiwan. 4. Department of Periodontology, School of Dentistry, National Defense Medical Center and Tri-Service General Hospital, Taipei, Taiwan. Electronic address: ndmcearl@ndmctsgh.edu.tw.
Abstract
OBJECTIVES: Osteonecrosis of the jaw (ONJ) is a potential side effect of bisphosphonate therapy. This Taiwanese national-scale cohort study aimed to investigate its incidence and risk of development by using a qualified control group with different demographic factors (age/gender), dental (tooth extraction/periodontal therapy) and medical (jaw radiotherapy) treatments, delivery routes (oral/intravenous), and diseases (diabetes/osteoporosis/cancer). METHODS: Data (n=958,136) from January 1, 2006 through December 31, 2008 were sourced from the Longitudinal Health Insurance Database 2005 of Taiwan. Cases of BRONJ were identified by three criteria modified from the definition proposed by the American Association of Oral and Maxillofacial Surgeons. The Cox proportional-hazards regression model and Kaplan-Meier estimates were used to analyse the results. RESULTS: The incidence densities of ONJ in the unexposed and bisphosphonate-exposed cohorts were estimated as 4.4 and 73.5 per 100,000 person-years, respectively (relative risk=16.8; 95% CI=6.0-37.5; P<0.001). Multivariate analysis revealed strong associations of delivery route, tooth extraction, and oral cancer with ONJ (hazard ratios=51.4 for oral bisphosphonates, 153.3 for intravenous bisphosphonates, 5.3 for tooth extraction, and 278.1 for oral cancer). CONCLUSIONS: These results not only demonstrate the incidence and relative risk of bisphosphonate-related ONJ in Taiwan but also indicate that tooth extraction and oral cancer may have a major impact on its development. CLINICAL SIGNIFICANCE: Physicians should be aware of individual patient risk factors before prescribing bisphosphonates. Bisphosphonate treatment is justified in the amelioration of life-threatening conditions in patients in whom ONJ would only affect quality of life.
OBJECTIVES:Osteonecrosis of the jaw (ONJ) is a potential side effect of bisphosphonate therapy. This Taiwanese national-scale cohort study aimed to investigate its incidence and risk of development by using a qualified control group with different demographic factors (age/gender), dental (tooth extraction/periodontal therapy) and medical (jaw radiotherapy) treatments, delivery routes (oral/intravenous), and diseases (diabetes/osteoporosis/cancer). METHODS: Data (n=958,136) from January 1, 2006 through December 31, 2008 were sourced from the Longitudinal Health Insurance Database 2005 of Taiwan. Cases of BRONJ were identified by three criteria modified from the definition proposed by the American Association of Oral and Maxillofacial Surgeons. The Cox proportional-hazards regression model and Kaplan-Meier estimates were used to analyse the results. RESULTS: The incidence densities of ONJ in the unexposed and bisphosphonate-exposed cohorts were estimated as 4.4 and 73.5 per 100,000 person-years, respectively (relative risk=16.8; 95% CI=6.0-37.5; P<0.001). Multivariate analysis revealed strong associations of delivery route, tooth extraction, and oral cancer with ONJ (hazard ratios=51.4 for oral bisphosphonates, 153.3 for intravenous bisphosphonates, 5.3 for tooth extraction, and 278.1 for oral cancer). CONCLUSIONS: These results not only demonstrate the incidence and relative risk of bisphosphonate-related ONJ in Taiwan but also indicate that tooth extraction and oral cancer may have a major impact on its development. CLINICAL SIGNIFICANCE: Physicians should be aware of individual patient risk factors before prescribing bisphosphonates. Bisphosphonate treatment is justified in the amelioration of life-threatening conditions in patients in whom ONJ would only affect quality of life.
Authors: M Kamimura; A Taguchi; M Komatsu; H Koiwai; R Ashizawa; A Ichinose; K Takahara; S Uchiyama; H Kato Journal: Osteoporos Int Date: 2018-11-20 Impact factor: 4.507
Authors: Tamás Vereb; Krisztina Boda; László Czakó; Mihály Vaszilkó; Gábor Fülöp; Gusztáv Klenk; Ágnes Janovszky; Ferenc Oberna; József Piffkó; László Seres Journal: J Clin Med Date: 2020-02-05 Impact factor: 4.241